翅工 ntroduction to Pharmaceutical Protein and Peptide Engineering Jesper Lau, PhD Vice President Protein Engineerin Novo Nordisk A/s Peptide synthesis pilot plai Bagsvaerd, Denmark A
Introduction to Pharmaceutical Protein and Peptide Engineering Jesper Lau, PhD Vice President Protein Engineering Novo Nordisk A/S Peptide synthesis pilot plant Bagsvaerd, Denmark
Presentation outline Novo nordisk Why engineer peptides(and proteins Type 2 diabetes The discovery of the first once daily gLp-1 Further engineering of long acting GLP-1 PLEASE INTERRUPT AND ASK!
• Novo Nordisk • Why engineer peptides (and proteins) • Type 2 diabetes • The discovery of the first once daily GLP-1 • Further engineering of long acting GLP-1 Presentation Outline 2 PLEASE INTERRUPT AND ASK!
PRODUCTS MARKETED IN AFFUIATES EN 75 Novo nordisk 180 COUNTRIE at a glance R&D CEntres IN CHINA. DENMARK Novo Nordisk is a global INDIA AND US healthcare company with more than 90 years of innovation and leadership in diabetes care. MEMPLOYS APPROXIMATELY DKK 42,000 PEOPLER This heritage has given us IN TOTAL REVENUE experience and capabilities that also enable us to help people defeat other serious chronic STRATEGIC conditions: haemophilia growth PRODUCTION SITES disorders and obesity. IN BRAZIL CHINA DENMARK 200,000 FRANCE AND US novonordisk fonden SHAREHOLDERS DISORDERS noVO LF OF THE 24, 400,000 WORLD'S INSULIN PEOPLE USE OUR PRODUCTS
Novo Nordisk at a glance Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Novo Nordisk - Corporate Presentation 3 3 Novo Nordisk - Corporate Presentatio n PRODUCTS MARKETED IN 180 COUNTRIES STRATEGIC PRODUCTION SITES IN BRAZIL, CHINA, DENMARK, FRANCE AND US SUPPLIER OF MORE THAN HALF OF THE WORLD’S INSULIN 24,400,000 PEOPLE USE OUR PRODUCTS AFFILIATES IN COUNTRIES R&D CENTRES IN CHINA, DENMARK, INDIA AND US DKK 111.8 BILLION IN TOTAL REVENUE 200,000 SHAREHOLDERS 75 EMPLOYS APPROXIMATELY 42,000 PEOPLE DIABETES OBESITY GROWTH DISORDERS HAEMOPHILIA
NOVO NORDISK MARKETS ITS PRODUCTS IN Our global DOENEMAREK 77 AFFILTATES 180 COUNTRIES presence WORLDWIDE REGIONAL HEADQUARTERS IC, EUROPE, US AND IO 5 STRATEGIC PRODUCTION SITES BRAZIL, CHINA, DENMARK, FRANCE, US 6 R&D CENTRES CHINA, DENMARK INDIA AND US
Our global presence Novo Nordisk - Corporate Presentation 4 REGIONAL 5HEADQUARTERS CHINA, PACIFIC, EUROPE, US AND IO R&D 6CENTRES CHINA, DENMARK, INDIA AND US STRATEGIC PRODUCTION SITES 5BRAZIL, CHINA, DENMARK, FRANCE, US 77AFFILIATES NOVO NORDISK MARKETS ITS PRODUCTS IN COUNTRIES 180 WORLDWIDE DENMARK GLOBAL HEADQUARTERS
Based on net turnover Novo nordisk is the 15th largest pharmaceutical company in the world Source: Novo Nordisk internal benchmark report based on individual annual reports published by each pharmaceutical compar changing Reported net turnover figures are converted in
Based on net turnover Novo Nordisk is the 15th largest pharmaceutical company in the world 0 50 100 150 200 250 300 350 400 450 (Billion DKK) Source: Novo Nordisk internal benchmark report based on individual annual reports published by each pharmaceutical company. Reported net turnover figures are converted into DKK